Alzheimer’s Coverage Debate Exposed Fault Lines in FDA and CMS Policy
A qualitative review of public comments on Medicare coverage for Alzheimer’s monoclonal antibodies found deep conflict over approval, access, equity, and value.
This section contains the website’s posts.